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Abstract
The main objective of this work is to compare the standard bioequivalence tests based on
individual estimates of the area under the curve and the maximal concentration obtained by
non compartmental analysis (NCA) to those based on individual empirical Bayes estimates
(EBE) obtained by nonlinear mixed eﬀects models. We evaluate by simulation the precision
of sample means estimates and the type I error of bioequivalence tests for both approaches.
Crossover trials are simulated under H0 using diﬀerent numbers of subjects (N) and of samples
per subject (n). We simulate concentration-time proﬁles with diﬀerent variability settings for
the between-subject and within-subject variabilities and for the variance of the residual error.
Bioequivalence tests based on NCA show satisfactory properties with low and high variabilities,
except when the residual error is high which leads to a very poor type I error or when n is
small which leads to biased estimates. Tests based on EBE lead to an increase of the type I
error when the shrinkage is above 20% which occurs notably when NCA fails. In those cases,
tests based on individual estimates cannot be used.
Keywords
pharmacokinetics; bioequivalence tests; non compartmental analysis; nonlinear mixed eﬀects
model; SAEM algorithm
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1 Introduction
Pharmacokinetic (PK) bioequivalence studies are performed to compare diﬀerent drug for-
mulations. The most commonly used design for bioequivalence trials is the two-period two-
sequence crossover design. This design is recommended by the Food and Drug Administration
(FDA) (1) and the European Medicines Evaluation Agency (EMEA) (2). FDA and EMEA
recommend to test bioequivalence from the log ratio of the geometric means of two parameters:
the area under the curve (AUC) and the maximal concentration (Cmax). These endpoints are
usually estimated by non compartmental analysis (NCA) using the trapezoidal rule to evaluate
AUC (3). NCA requires few hypotheses but a large number of samples per subject (usually
between 10 and 20).
PK data can also be analyzed using nonlinear mixed eﬀects models (NLMEM). This method
is more complex than NCA but has several advantages: it takes beneﬁt of the knowledge ac-
cumulated on the drug and can characterize the PK with few samples per subject. This allows
to perform analyses in patients, the target population, and in whom pharmacokinetics can
be diﬀerent from healthy subjects. Non compartmental AUC is computed by trapezoidal rule
which ignores assay error. NCA does not take into account non linear pharmacokinetics, which
can bias the bioavailability estimation (4) and may amplify small bioavailability diﬀerences be-
tween drug products (5). The European guideline on similar biological medicinal products,
which frequently exhibit non linear pharmacokinetics, recommends to estimate in the com-
parative PK studies, the elimination characteristics such as clearance (6). It is known that
in these conditions, clearance is not accurately estimated by NCA. Models can also lead to
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better understanding of the biological system than a fully empirical approach and therefore
help interpret ambiguous results.
However, the use of NLMEM is still rare in early phases of drug development or to analyze
crossover studies. There are only seven published studies which use NLMEM to analyze bioe-
quivalence trials (7, 8, 9, 10, 11, 12, 13) and except in Zhou et al (12), all analyze a dataset with
many samples per subject. Five papers (7, 8, 9, 10, 13) compare tests based on individual NCA
estimates to tests based on NLMEM and all conclude that the results are similar. Yet, they use
diﬀerent statistical approaches to test bioequivalence with NLMEM. Furthermore, none per-
form bioequivalence tests on individual estimates of AUC and Cmax obtained from NLMEM.
Pentikis et al (8) propose the estimation of AUC and Cmax by standard nonlinear regression as
an alternative to the NCA and Zhou et al (12) perform bioequivalence tests on the individual
empirical Bayes estimates (EBE) of the volume of distribution and the steady-state through
concentration. Otherwise, bioequivalence tests are performed on treatment eﬀect parameters
(7, 8, 9, 10, 11, 13). All authors agree that simulation studies are needed to evaluate bioequiva-
lence tests based on NLMEM and to compare them to tests based on individual NCA estimates.
In this work, we compare the standard analysis of bioequivalence crossover trials based on
NCA to the same usual analysis based on individual EBE obtained by NLMEM. We study the
inﬂuence of the design for each approach. There is already one published simulation study of
Panhard and Mentré which evaluates bioequivalence tests based on EBE estimated through
NLMEM (14). Our present study relies on the work of Panhard and Mentré as starting point
and adds several new features.
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The major distinctness concerns the studied tests on the individual estimates (EBE or NCA).
Panhard and Mentré perform the Student paired test and the Wilcoxon paired signed rank test
whereas we use a linear mixed eﬀects model (LMEM). As speciﬁed in the regulatory guidelines
(1, 2), the bioequivalence analysis should take into account sources of variation that can be
reasonably assumed to have an eﬀect on the endpoints AUC and Cmax. Therefore, LMEM
including treatment, period, sequence and subject eﬀects are usually used to analyze the log-
transformed data (15).
Panhard and Mentré limit their comparison to bioequivalence tests on AUC and do not evalu-
ate tests based on Cmax. In the present study, both endpoints are analyzed; indeed we expect
some issues for bioequivalence test performed on Cmax as the estimation of Cmax by NCA is
sensitive to the design and the computation of Cmax from EBE is more complex than for AUC.
To simulate PK proﬁles and then to estimate individual parameters by NLMEM, Panhard and
Mentré use a pharmacokinetic model parametrized using AUC as one of the PK parameters
whereas we choose a more common parameterization, replacing AUC by the clearance of the
drug.
For the estimation of NLMEM parameters, Panhard and Mentré use an algorithm based on a
ﬁrst order linearization with respect to the random eﬀects, the ﬁrst order conditional estimates
(FOCE) algorithm (16) implemented in the R function nlme (17). The FOCE algorithm is
the more widely used algorithm and corresponds to the industry standard for model-based
PK analyses as it is implemented in NONMEM . Yet, this algorithm presents some conver-
gence issues which could be avoided with the use of a stochastic algorithm using the exact
maximum likelihood, such as the stochastic approximation expectation maximisation (SAEM)
algorithm (18, 19, 20). The SAEM algorithm is implemented in the free software MONOLIX
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(21) (ﬁrst version February 2005) and is applied to several population PK analyses (22, 23, 24).
The main objective of this work is to compare standard bioequivalence tests based on
individual estimates of AUC and Cmax obtained by NCA or by NLMEM. The comparison is
based on the precision of the sample means of log(AUC) and log(Cmax) and on the type I error
of bioequivalence tests for both estimation methods. In section 2 of the article, we describe the
model, the simulation study, both estimation methods (NCA and NLMEM), the evaluation of
precsion of sample means, how bioequivalence tests are performed and how shrinkage on the
tested parameters is estimated. The main results of the simulation are exposed in section 3.
Finally, the study results and perspectives are discussed.
2 Methods
2.1 Simulation study
2.1.1 Simulation model
We analyze two-period two-sequence crossover PK trials where subjects are randomly allo-
cated to one of two treatment sequences. In the ﬁrst sequence (Ref − Test), subjects receive
the reference treatment (Ref) and the test treatment (Test) in period one and two, respec-
tively. In the second sequence (Test− Ref), subjects receive treatments in the reverse order
(Test then Ref). Designs are balanced, i.e. there is the same number of subjects N/2 for each
sequence.
In the following, we denote yijk the concentration for individual i (i = 1, · · · , N) at sampling
time j (j = 1, · · · , nik) for period k (k = 1, 2). We also denote f the nonlinear pharmacokinetic
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function which links concentrations to sampling times. The nonlinear mixed eﬀects model can
be written as follows:
yijk = f(tijk, θik) + ǫijk (1)
where θik = (θikl; l = 1, · · · , p)′ is the p-vector of the PK parameters of subject i for period k.
ǫijk is the residual error assumed to be normally distributed with zero mean and variance σ
2
ijk,
with:
σ2ijk = (a+ b f(tijk, θik))
2 (2)
This is a combined error model with two parameters: a for the additive and b for the propor-
tional part. We assume a multivariate log-normal distribution for the individual parameters
θik. In absence of covariates, the l
th individual parameter can be decomposed as:
θikl = µl e
ηil +κikl (3)
with µ = (µl ; l = 1, · · · , p)′ the p-vector of ﬁxed eﬀects, ηi = (ηil ; l = 1, · · · , p)′ the vector
of random eﬀects of subject i and κik = (κikl ; l = 1, · · · , p)′ the vector of random eﬀects of
subject i at period k. ηi represents the variability between individuals and it is named between-
subject variability (BSV). κik represents the variability between two periods of treatment for
the same individual and it is called within-subject variability (WSV). ηi and κik are assumed
to be normally distributed with zero mean and with covariance matrices of size p× p denoted
Ω and Γ, respectively. In this study, we assume that Ω and Γ are diagonal. ηi, κik and ǫijk are
assumed to be independent.
We introduce three categorical covariates into the statistical model: the treatment Tik, the
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period Pk and the sequence Si. The reference classes for each covariate are deﬁned as follows:
Tik is ﬁxed to zero for the treatment Ref and is equal to 1 for the treatment Test; Pk is ﬁxed
to zero for the ﬁrst period and is equal to 1 for the second one; Si is ﬁxed to zero for the ﬁrst
sequence Ref−Test and is equal to 1 for the second one Test−Ref . βT = (βT,l ; l = 1, · · · , p)′,
βP = (βP,l ; l = 1, · · · , p)′ and βS = (βS,l ; l = 1, · · · , p)′ correspond to vectors of the treatment,
period and sequence eﬀect. With these three covariates, µl of Eq.(3) is replaced by µikl deﬁned
as:
µikl = λl e
βT,l Tik + βP,l Pk + βS,l Si (4)
with λ = (λl ; l = 1, · · · , p)′ the p-vector of the ﬁxed eﬀects for the reference classes.
2.1.2 Theophylline pharmacokinetics
We use the concentration data of the anti-asthmatic drug theophylline to deﬁne the popula-
tion PK model for the simulation study. These data are classical ones in population pharma-
cokinetics (17) and are used in previous simulation studies done by Panhard et al. (14, 25).
The theophylline data include twelve subjects receiving a single oral dose of theophylline de-
pending on their body weight (from 3 to 6mg). For each patient, ten blood samples were taken
at 0.25, 0.5, 1, 2, 3.5, 5, 7, 9, 12 and 24 h after administration and serum concentrations were
measured. A one compartment model with ﬁrst order absorption and ﬁrst order elimination
adequally describes the data and can be written as follows:
f(t, θ) =
FDka
CL− V ka
(
e−ka t − e−CL/V t
)
(5)
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where D is the dose, F the bioavailability, ka the absorption rate constant, CL the clearance of
the drug and V the volume of distribution. As only data after oral administration are obtained,
the bioavailability cannot be estimated and, consequently, the vector θ of PK parameters is
equal to (ka, CL/F, V/F ).
2.1.3 Simulation features
In this simulation study, we use rather similar settings as those of the simulation studies
performed by Panhard et al. (14, 25). However we simulate two-period, two-sequence crossover
pharmacokinetic trials whereas they simulate two-period, one-sequence crossover trials. For
each trial, N/2 subjects are allocated to the sequence Ref−Test andN/2 subjects are allocated
to the sequence Test − Ref . We ﬁx the dose for all subjects to 4 mg which corresponds to
the rounded median dose of the theophylline study. The vector of population parameters
λ is composed of (λka = 1.48 h
−1, λCL/F = 40.36 mL/h, λV/F = 0.48 L) for the reference
treatment. In order to mimic a change in bioavailability, we add a treatment eﬀect βT =
(0, βT,CL/F , βT,V/F )
′ on log(λ), i.e. we multiply λCL/F by e
βT,CL/F and λV/F by e
βT,V/F for
the test treatment. The modiﬁcation of bioavailability also aﬀects AUC and Cmax. Indeed,
AUC = FD/CL and Cmax is deﬁned as:
Cmax = f(tmax, θ) =
FD
V
e−CL/V tmax
with tmax =
log(ka)− log(CL/V )
ka − CL/V
(6)
We do not simulate a period eﬀect or a sequence eﬀect. We simulate with two levels of
variability for the between-subject and within-subject variability. In the following, BSV and
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WSV are given as standard deviations of the log-transformed parameters multiply by 100 to
be expressed in percent. The standard deviation on the log scale corresponds approximately
to the coeﬃcient of variation on the ordinary scale. For the low level, we ﬁx BSV to 20% for ka
and CL/F and to 10% for V/F ; WSV is ﬁxed to half BSV for the three parameters. For the
high level, we ﬁx BSV to 50% and WSV to 15% for the three parameters. We also simulate
with two levels of variability for the residual error: a = 0.1 mg/L, b = 10% for the low level,
and a = 1 mg/L, b = 25% for the high level. The high level of residual error is only used
with the high level of BSV and WSV. We call Sl,l, the variability setting with low variability
for BSV and WSV and for the residual error, Sh,l, the variability setting with high variability
for BSV and WSV and low for the residual error, and Sh,h, the variability setting with high
variability for BSV and WSV and for the residual error. The three variability settings are
summarized in Table I.
2.1.4 Simulation process
For each subject i = 1, · · · , N of each simulated trial m = 1, · · · ,M , we simulate a vector
of random eﬀects ηi in N (0,Ω) and two vectors of random eﬀects κik in N (0,Γ), one for each
period k = 1, 2. To get the logarithm of each individual parameters log(θikl), we add the
logarithm of the mean parameter log(λl), the treatment eﬀect βT,l if needed (depending on the
treatment group and the PK parameter considered), and both random eﬀects ηil and κikl. The
concentrations f(tijk, θik) predicted by the PK model at time tijk (j = 1, · · · , nik) are then
computed using the individual parameters. In these simulations, the sampling times for all
subjects and both periods are similar. So j = 1, · · · , n, where n is a ﬁxed number of sampling
times for each simulated design. Finally, we add a residual error, generated from a normal
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distribution N (0, (a+ b f(tijk, θik))2), to each predicted concentration to obtain the simulated
concentrations yijk. We do not incorporate in the simulation a limit of quantiﬁcation (LOQ)
because NCA cannot handle such data, contrary to the SAEM algorithm, and we do not want
to favour the later. In the rare cases where the simulated concentration is below zero, we ﬁx
it to the value 0.1 mg/L.
We expect more of these ﬁxed concentrations when variability increases but their proportion
could also diﬀer from a design to another if the sampling times diﬀer. Consequently, for each
simulated design and each variability setting, we compute the proportion of the concentrations
ﬁxed to 0.1 mg/L and study the corresponding sampling times.
2.1.5 Simulation designs
We simulate trials with four diﬀerent designs, which are also used by Panhard et al (14, 25).
We simulate with the original design with N = 12 subjects and n = 10 samples per subject
and per period, taken at the times of the initial study (0.25, 0.5, 1, 2, 3.5, 5, 7, 9, 12 and
24 h after dosing). We also simulate with an intermediate design with N = 24 subjects
and n = 5 samples, taken at 0.25, 1.5, 3.35, 12 and 24 h after dosing, a sparse design with
N = 40 subjects and n = 3 samples, taken at 0.25, 3.35 and 24 h after dosing and a rich
design N = 40 subjects and n = 10 samples, taken at the times of the initial study. For each
design, we simulate using the variability settings Sl,l and Sh,l. We simulate using Sh,h only
for the intermediate design. For each design and each variability setting, we simulate 1000
trials under two diﬀerent hypotheses: H0;80% where βT = (0, log(0.8), log(0.8))
′ and H0;125%
where βT = (0, log(1.25), log(1.25))
′. For each simulated trial, each simulated design and each
variability setting, the simulated concentrations for the reference treatment are equal in both
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simulated hypotheses. In the following, we call simulation setting the association of one design
with one variability setting and one hypothesis (H0;80% or H0;125%). Considering this, there
are 18 diﬀerent simulation settings (8 for Sl,l and Sh,l, and 2 for Sh,h). All simulations are
performed using the statistical software R 2.7.1. Figure 1 displays the individual data of one
trial simulated under H0;80% and H0;125% with the intermediate design and three variability
settings (Sl,l, Sh,l and Sh,h).
2.2 Estimation of individual parameters
2.2.1 Notations
We perform bioequivalence tests on AUC and Cmax. To estimate the individual parameters
using NCA or NLMEM, we do not consider periods or sequences. Only the treatment group
(Ref or Test) is taken into account. For each simulated trialm = 1, · · · , 1000 of one simulation
setting, there are 2N individual AUC and 2N individual Cmax, one for each subject i =
1, · · · , N and each treatment group.
In the following, for one simulated trial, we call AUC
(Ref)
i the true value of the individual AUC
of subject i for the reference treatment and AUC
(Test)
i the true value of the individual AUC
of subject i for the test treatment; we also deﬁne ÂUC
(Ref)
i the estimated value of individual
AUC of subject i for the treatment Ref obtained from NCA or NLMEM and ÂUC
(Test)
i the
corresponding AUC for the treatment Test.
Same notations are applied to Cmax. C
(Ref)
max i and C
(Test)
max i are the true value of the individual
Cmax of subject i for the treatment Ref and Test, respectively. Ĉmax
(Ref)
i and Ĉmax
(Test)
i are
the corresponding estimated value of individual Cmax obtained from NCA or NLMEM.
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In some cases, we may refer to these diﬀerent individual parameters without specifying the
treatment group. For each simulated trial, AUC
(Ref)
i , AUC
(Test)
i , C
(Ref)
max i and C
(Test)
max i are
computed from the corresponding individual parameters ka, CL/F and V/F simulated as
described in section 2.1.4.
2.2.2 Estimation based on non compartmental analysis
First, we estimate AUC and Cmax by non compartmental analysis (3) using a R function
named mnca which we develop. For each simulated trial, this function provides the estimation
of diﬀerent NCA parameters for each subject and each treatment group. Diﬀerent options
have to be speciﬁed in mnca. In this study, we use the linear trapezoidal rule to compute the
AUC0−last between the time of dose (equal to 0) and the last sampling time. To obtain the
total AUC (between the time of dose and inﬁnity), we compute the terminal slope equal to
CL/V using the logarithm of the last concentrations to perform a linear regression. To do so,
we use a ﬁxed number of concentrations which depends on the number of samples per subject
in the design.
To avoid biased estimation of the terminal slope, the ﬁrst point used for its computation
should be on the descending side of the concentration curve and not too close to Cmax. Using
the mean value of PK parameters, tmax, the sampling time corresponding to Cmax, is about
2.06 h for both treatment groups (contrary to Cmax, tmax is not aﬀected by the change of
bioavailability). Consequently, for the original and rich designs where n = 10, we use the last
four concentrations which correspond to sampling times 7, 9, 12 and 24 h. NCA is normally
performed on PK proﬁles containing ten sampling times per subject or more. For intermediate
and sparse designs where n = 5 and n = 3 respectively, the total AUC is estimated by NCA
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for completeness. For these two designs, we use the last two concentrations which correspond
to sampling times 12 and 24 h for the intermediate design, and to 3.35 and 24 h for the sparse
design.
Figure 2 displays the individual concentration curves of one simulated trial for the original,
intermediate and sparse designs and the two variability settings Sl,l and Sh,l. The bottom
left graphic of the Figure 1 presents a similar graphic for the intermediate design and Sh,h,
completing our illustration. For rich and intermediate designs, the number of concentrations
used to compute the terminal slope seems reasonable. Same observation can be done for the
rich design because the sampling times are similar to those of the original design, only the
number of subjects diﬀers. For sparse design, the number of concentration used to compute
the terminal slope is chosen by default, ﬁrst point being close to Cmax.
Other assumptions are made to compute the terminal slope, to handle particular PK proﬁles,
especially for the intermediate and sparse designs where only two points are used for the
estimation. If the last two concentrations increase instead of decreasing or if they are similar
up to the sixth digit, we consider the terminal slope be missing, i.e. there is no estimation
of the total AUC for the subject and treatment concerned. The proportion of missing ÂUCi
should increase with variability and could diﬀer from a design to another due to diﬀerent
sampling times. Consequently, for each design and each variability setting, we compute the
proportion of missing ÂUCi.
For all designs, Cmax is estimated as the maximal concentration observed. Contrary to AUC,
there is no missing Cmax.
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2.2.3 Estimation based on nonlinear mixed effects model
We also estimate AUC and Cmax from the individual empirical Bayes estimates of the PK
parameters after population analyses. In this study, we use the SAEM algorithm implemented
in MONOLIX 2.4 to estimate the NLMEM parameters (population and individual parameters).
For each simulated trial, we analyze separately the concentrations of each treatment group
using NLMEM without taking into account periods and sequences. As each subject receives
both treatments, data of each treatment group contain observations from all subjects. In the
following, we describe the statistical model used to ﬁt the data of the reference treatment. We
consider y
(Ref)
ij the concentration for individual i (i = 1, · · · , N) at time tij (j = 1, · · · , n)
and for the treatment Ref . Depending on the sequence of the subject i, y
(Ref)
ij corresponds to
concentration of the ﬁrst or second period. The statistical model used has no covariate because
no period or sequence eﬀect are incorporated. Furthermore, since periods are not considered,
WSV cannot be separated from BSV. Consequently, the lth individual parameter is deﬁned as:
θ
(Ref)
il = µ
(Ref)
l e
η
(Ref)
il (7)
Ω (Ref) is the covariance matrix of the vector of random eﬀects η
(Ref)
i . A similar statistical
model is applied to ﬁt the data of the treatment Test.
Of note, given the BSV and WSV, the overall variability is equal for both treatment groups,
i.e. Ω (Ref) = Ω (Test). However, for each simulated trial, their estimates, Ω̂ (Ref) and Ω̂ (Test),
are diﬀerent. The overall simulated variability is 22.4% for ka and CL/F and 11.2% for V/F
under Sl,l, and 52.2% for the three PK parameters under Sh,l and Sh,h.
After having estimated the population parameters for the data of one treatment group of one
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simulated trial, we estimate the conditional modes of the corresponding individual parameters
which are deﬁned as the individual empirical Bayes estimates. These EBE provide the individ-
ual estimates of PK parameters (ka, CL/F and V/F ). We then derive individual ÂUC
(Ref)
i
and Ĉmax
(Ref)
i or ÂUC
(Test)
i and Ĉmax
(Test)
i depending on the treatment group considered.
Contrary to NCA, there is no missing ÂUCi obtained by NLMEM using the SAEM algorithm.
2.2.4 Evaluation of estimates of sample means
In this study, we compute individual ÂUC i and Ĉmax i for 1000 replicates of diﬀerent designs,
diﬀerent variabilities and diﬀerent treatment groups using two types of estimation. To analyze
and compare the accuracy and precision of the estimates of the sample means of log(AUC) and
log(Cmax) using NCA or EBE, we compute estimation error for each treatment group (Ref
or Test) of each simulated trial. To take into account sampling variability, for each dataset
we compute the estimation error as the diﬀerence between the sample mean of the estimates
(NCA or EBE) and the sample mean of the true simulated values. In the following, deﬁnitions
are given for ÂUC
(Ref)
i . Same deﬁnitions apply to ÂUC
(Ref)
i , Ĉmax
(Ref)
i and Ĉmax
(Test)
i .
For each simulated trial, the estimation error for the sample mean of log(AUC) for the reference
treatment is computed as:
ee
(Ref)
AUC =
1
N∗
N∗∑
i=1
log(ÂUC
(Ref)
i )−
1
N
N∑
i=1
log(AUC
(Ref)
i ) (8)
with ÂUC
(Ref)
i the AUC estimated by NCA or derived from EBE for subjects i = 1, · · · , N
∗,
and AUC
(Ref)
i the true simulatd parameter for subjects i = 1, · · · , N . For the estimation of
individual parameters by NCA, there may be missing ÂUC i, so that N
∗ ≤ N .
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For one simulation setting, we call ee
(Ref)
AUC,m the estimation error for the sample mean of
log(AUC) computed for the reference treatment and themth simulated trial (m = 1, · · · , 1000).
We then deﬁne the bias and root mean square error (RMSE) computed from ee
(Ref)
AUC,m over the
1000 replicates as:
bias
(Ref)
AUC =
1
1000
1000∑
m=1
ee
(Ref)
AUC,m
rmse
(Ref)
AUC =
√√√√ 1
1000
1000∑
m=1
(ee
(Ref)
AUC,m)
2
(9)
As well as computing bias and RMSE, we compute the 95% conﬁdence interval of bias
(Ref)
AUC
using the standard error of the mean and the 97.5% quantile of the Gaussian distribution. If
zero does not belong to the 95% conﬁdence interval of bias
(Ref)
AUC , we can conclude that bias is
signiﬁcantly diﬀerent from zero with a type I error of 5%.
2.3 Bioequivalence test
2.3.1 Implementation of the two one-sided tests
We perform the standard bioequivalence analysis recommended by FDA and EMEA (1, 2).
The individual parameters are log-transformed and analyzed using a linear mixed eﬀects model
written as follows:
log(θikl) = νl + βT,l Tik + βP,l Pk + βS,l Si + ξil + ǫikl (10)
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where θikl represents the l
th individual parameter (AUC if l = 1 or Cmax if l = 2) for subject
i (i = 1, · · · , N) at period k (k = 1, 2). νl is the mean value for the studied log-transformed
metric. The three covariates Tik, Pk and Si, for treatment, period and sequence are deﬁned as
before. It is assumed that the random subject eﬀect ξil (l = 1, 2) and the residual error ǫikl
(l = 1, 2) are independently normally distributed with zero mean.
For each simulation setting, the individual estimates ÂUC i and Ĉmax i obtained from NCA
and NLMEM are analyzed by the LMEM described above. To check the properties of the
TOST, we also analyze the true simulated value AUCi and Cmax i. As speciﬁed before, for
AUC estimated by NCA, they may be missing ÂUC i. In that case, the LMEM is performed
on less than 2N ÂUC i.
After ﬁtting the LMEM to individual metrics, a bioequivalence test is performed on the
estimate of treatment eﬀect β̂T,l. The null hypothesis of the bioequivalence test recom-
mended by the guidelines (1, 2) and performed on the lth individual parameter is H0: {βT,l ≤
log(0.8) or βT,l ≥ log(1.25)}. H0 is rejected if the 90% conﬁdence interval (90% CI) of β̂T,l lies
within [log(0.8); log(1.25)]. These limits of the bioequivalence test correspond to a ratio of the
geometric mean falling within 80%-125%. This approach based on the 90% CI is equivalent to
Schuirmann’s two one-sided tests (TOST) procedure (26). H0 is composed of two unilateral
hypotheses {βT,l ≤ log(0.8)} and {βT,l ≥ log(1.25)}. Both are tested separately by a one-sided
test with a type I error of 5%. The p-value of the TOST is the maximum of both p-values of
the one-sided tests and for each test the limit is the 95% quantile of the Student distribution
with df degrees of freedom.
For balanced datasets, the N/2 subjects of each sequence are considered as two independent
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samples from normal populations with equal variances, and df = N − 2 (15, 27). For un-
balanced datasets, i.e. when there is one or more missing ÂUC i in a dataset for NCA, the
determination of the degrees of freedom is more complex. Diﬀerent approximations are avail-
able as for example the containment method (28), the Kenward-Roger adjustment (29) or
the Satterthwaite’s procedure approximation (28, 29). In this study, we use the R function
lme from the package nlme to perform the LMEM in which the degrees of freedom are esti-
mated using the containment method (17). There, the degrees of freedom are calculated as:
df = nobs − N − 2 where nobs is the total number of individual parameters. When there is
no missing value, this approach coincides with the degrees of freedom computed in balanced
datasets (because then nobs = 2N).
2.3.2 Evaluation of the type I error
Bioequivalence tests are evaluated for ÂUC i and Ĉmax i estimated by NCA or NLMEM on
trials simulated under the composite null hypothesis H0. Bioequivalence tests are also per-
formed on the true simulated values AUCi and Cmax i. The type I error of the TOST procedure
is deﬁned as the supremum of the type I errors over the null space (30). It corresponds to the
supremum of the type I error of the two one-sided tests. As suggested by Liu and Weng (31),
the type I error of the bioequivalence test can be evaluated for each boundary of H0 space, i.e.
log(0.8) and log(1.25). Consequently, we simulate for each design of each variability setting
1000 trials under each unilateral hypothesis H0;80% and H0;125% as speciﬁed before.
For each unilateral hypothesis H0;80% and H0;125%, the type I error is estimated by the propor-
tion of the simulated trials for which the null hypothesis H0 is rejected. If the bioequivalence
tests were performed on the true parameters (AUCi and Cmax i), the results of both type I
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errors should be identical because H0;80% and H0;125% are symetric but we are working with
estimates. As proposed by Panhard and Mentré (14), we deﬁne the global type I error as the
maximum value of both type I errors estimated. Due to the 1000 replicates, the 95% prediction
interval (95% PI) for a type I error of 5% is [3.7%; 6.4%].
2.3.3 Shrinkage and tests based on empirical Bayes estimates
It is known in NLMEM that, with sparse individual information, the individual estimates of
random eﬀects shrink towards their mean value which is zero (32). For the reference treatment
group of each simulated trial, the shrinkage on the lth individual EBE (ka, CL/F or V/F ) can
be deﬁned as:
Sh
(Ref)
l = 1−
var(η̂
(Ref)
il )
ω̂
(Ref) 2
l
(11)
where var(η̂
(Ref)
il ) is the empirical variance of the l
th individual estimated random eﬀects and
ω̂
(Ref) 2
l is the estimated variance of the corresponding random eﬀects.
AUC and Cmax are secondary parameters of the NLMEM because they are deﬁned as
functions of the PK parameters, ka, CL/F and V/F . As the shrinkage on individual EBE,
the shrinkage on log(AUC) and log(Cmax) can also be computed. Consequently, we can study
the link between the type I error of bioequivalence tests based on EBE and the amount of
shrinkage.
For log(AUC), Eq.(11) can be expressed as:
Sh
(Ref)
AUC = 1−
var(log(ÂUC
(Ref)
i ))
ω̂ 2
AUC (Ref)
(12)
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where var(log(ÂUC
(Ref)
i )) is the empirical variance of the individual estimates log(ÂUC
(Ref)
i )
and ω̂ 2
AUC (Ref)
is its estimated variance in the model. As log(AUC) = log(D) − log(CL/F ),
ω 2
AUC (Ref)
= ω 2
CL/F (Ref)
and ω̂ 2
AUC (Ref)
is the estimated value ω̂ 2
CL/F (Ref)
.
For one simulation setting, we call Sh
(Ref)
AUC,m the shrinkage on log(AUC) computed for the
reference treatment for the mth simulated trial (m = 1, · · · , 1000). To summarize the 1000
Sh
(Ref)
AUC,m of each simulation setting, we compute the median shrinkage over these 1000 values.
Eq.(12) can be applied to log(Cmax); var(log(Ĉmax
(Ref)
i )) is computed from the individual
estimates as for AUC. As the deﬁnition of Cmax given in Eq.(6) is complex, the variance of
log(Cmax) for the reference treatment, ω
2
C
(Ref)
max
cannot be computed from ω 2
k
(Ref)
a
, ω 2
CL/F (Ref)
and
ω 2
V/F (Ref)
. It must be approximated for instance using the delta method (33). The expression
and details are given in Appendix. As for AUC, the median shrinkage over the 1000 values of
Sh
(Ref)
Cmax, m
is computed for each simulation setting.
3 Results
3.1 Simulated data and missing values
As explained in section 2.1.4, if the simulated concentration is below zero, it is ﬁxed to 0.1
mg/L. As expected, the proportion of these ﬁxed concentrations diﬀers from one variability
setting to another and from one design to another, except for the original and rich design where
the sampling times are similar. The maximal proportion is rather small and is 0.03% for Sl,l,
1.6% for Sh,l and 8.5% for Sh,h. For Sl,l, all ﬁxed concentrations correspond to the last sam-
pling time which is 24 h for all designs. For Sh,l, there are ﬁxed concentrations corresponding
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to diﬀerent sampling times but ﬁxed concentrations at 24 h are majoritary, with a minimal
proportion of 90%. For Sh,h, ﬁxed concentrations corresponds mostly to 24 h (54%) and then
mainly to 0.25 h (20%) and 12 h (19%).
Over all the simulations, some ÂUC i estimated by NCA are missing due to particular
individual PK proﬁles (see section 2.2.2). The proportion of missing ÂUC i is similar in both
hypotheses and remains rare for the four designs of Sl,l and Sh,l. For both variability settings,
the maximal proportion corresponds to the intermediate design (N = 24, n = 5) with 0.02%
and 3.3% for Sl,l and Sh,l, respectively. This proportion is 25% for Sh,h. Among missing
ÂUCi of Sh,h, 12% are due to concentrations ﬁxed to 0.1 mg/L, i.e. due to two similar last
concentrations. Other missing ÂUCi are due to two last concentrations increasing instead
of decreasing. As expected, there is no simulated trial where all ÂUC i for both treatment
groups are missing. In other words, the estimation error for the sample mean of log(AUC) or
log(Cmax) is computed on the 1000 simulated trial for each simulation setting, and the type
I errors of bioequivalence test are estimated on 1000 replicates for AUC and Cmax for both
hypotheses H0;80% and H0;125%.
3.2 Evaluation of estimates of sample means
Figure 3 displays the bias (top) and RMSE (bottom) on sample mean estimates for log(AUC)
(left) and log(Cmax) (right) estimated for the reference treatment. Results are similar for both
treatment groups (Ref and Test) and both unilateral hypotheses (results not shown). The
95% conﬁdence interval of the bias is not shown in Figure 3 because this interval is tighter than
the width of the displayed symbol and all biases are signiﬁcantly diﬀerent from zero. There is
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more bias and larger RMSE for NCA than for EBE for all designs and all variability settings.
Note that biases and RMSE are computed on log scale, so that, for instance, a value of 0.038
corresponds approximatively to an error of 3.8% on the ordinary scale for the geometric mean.
For NCA estimates, the bias and RMSE increase when the number of samples per subject
decreases and are lower for Sl,l compared to Sh,l. For the intermediate design (N = 24, n = 5),
the bias on the sample mean of log(AUC) is 0.038, 0.094 and 0.15 for Sl,l, Sh,l and Sh,h,
respectively; RMSE is 0.044, 0.12 and 0.21, respectively.
For individual estimates based on EBE, the bias is small (less than 0.02) for both parameters
(log(AUC) and log(Cmax)), all designs and all variability settings whereas RMSE increase
when the number of samples per subject decreases and is majoritary lower for Sl,l compared
to Sh,l. For instance, for the intermediate design, the bias on the sample mean of log(AUC) is
-0.0096, -0.016 and -0.010 for Sl,l, Sh,l and Sh,h respectively; RMSE is 0.019, 0.031 and 0.10,
respectively.
3.3 Bioequivalence test
Table II and Figure 4 provide the results of the type I error of bioequivalence tests per-
formed on the treatment eﬀect of log(AUC) and log(Cmax). Table II contains the estimated
type I error for each unilateral hypothesis, each design of each variability setting, for the true
simulated values and both types of estimates (NCA and EBE). Figure 4 represents the global
type I error for log(AUC) (top) and log(Cmax) (bottom) versus the design for each variability
setting and both types of estimates. The global type I error is deﬁned as the supremum of
both estimated type I errors.
For the bioequivalence test performed on the true simulated values, the type I error for all
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designs, all variability settings and both null hypotheses lie in the 95% PI of the nominal level
showing the good performance of the TOST. Mostly, for one type of estimates (NCA or EBE)
and one design of one variability setting, the type I errors of both hypotheses are close.
For log(AUC), the global type I error of test based on NCA estimates lies between the 95%
PI of the nominal level for the four designs of Sl,l and Sh,l and it is much too conservative for
Sh,h. For instance, for the intermediate design, the global type I error is respectively 4.3%,
5.2% and 0.8% for Sl,l, Sh,l and Sh,h. For Cmax, test based on NCA estimates has a correct
global type I error for the original and intermediate designs simulated with Sl,l and Sh,l. The
global type I error is above the 95% PI for the sparse design (N = 40, n = 3) simulated with
Sl,l and Sh,l and the intermediate design simulated with Sh,h.
Surprisingly, tests based on EBE often lead to an increased type I error especially for the
sparse design. For AUC, the global type I error remains at the nominal level for the rich
design (N = 40, n = 10). For Cmax, the global type I error lies between the 95% PI for the
rich and the original designs simulated with Sl,l. The global type I error increases when the
number of samples per subject decreases and is lower for Sh,l compared to Sl,l and Sh,h. Most
of the type I errors are below 10% for Sl,l and Sh,l. For AUC and the intermediate design, the
global type I error is respectively 8.0%, 7.1% and 22.2% for Sl,l, Sh,l and Sh,h.
Figure 5 represents the global type I errors of bioequivalence tests for the treatment eﬀect on
log(AUC) (top) and log(Cmax) (bottom) obtained from NLMEM versus the median shrinkage
on the corresponding parameter for the reference treatment. The distribution of the shrinkage is
similar for both treatment (Ref and Test) and both unilateral hypotheses (results not shown).
For both parameters, the median shrinkage is lower for Sh,l than for Sl,l. For log(AUC), the
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median shrinkage is also higher for Sh,h than for Sh,l. There is a clear relationship between the
inﬂation of the global type I error and the amount of shrinkage with type I error greater than
15% for shrinkage greater than 20%.
4 Discussion
In this study, we compare the standard bioequivalence analysis performed on individual es-
timates of AUC and Cmax obtained by NCA to the same bioequivalence analysis performed on
individual EBE obtained by NLMEM. To do so, we perform a simulation study with diﬀerent
designs and diﬀerent levels of variability. The estimation of parameters and the type I error
are evaluated for both types of estimates.
Compared with the simulation study of Panhard and Mentré (14), we use the bioequivalence
analysis recommended in the guidelines (1, 2) and we study both parameters (AUC and Cmax).
Besides, the simulation study of Panhard and Mentré is performed using the FOCE algorithm
implemented in R function nlme. The FOCE algorithm is widely used to perform popula-
tion PK analyses but, in simulation studies which compared diﬀerent algorithms available,
stochastic EM algorithms (like the SAEM algorithm) obtained the best results for accuracy
and precision of estimates (34, 35).
As Panhard and Mentré, we simulate under both null hypotheses assuming a modiﬁcation
in the bioavailability F , i.e. assuming the same modiﬁcation for CL/F and V/F which also
aﬀects similarly both tested parameters AUC and Cmax. Consequently, the number of sim-
ulations are reduced because the unilateral hypothesis H0;80% (H0;125% respectively) for AUC
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corresponds to the unilateral hypothesis H0;80% (H0;125% respectively) for Cmax; the same set
of simulations is used for both parameters. However, other choices may be suitable as any
PK parameter is likely to change between two formulations of the same drug. For instance,
a change in the elimination rate CL/V due to interaction with excipient could be possible (36).
Furthermore, we study only a one compartment model. We do not simulate multi-compartmental
models. For both types of estimates (NCA and EBE), we perform bioequivalence test on AUC
and Cmax. Even with a multi-compartmental model, PK parameters would be summarized
with these two endpoints even though the relationship between Cmax and the PK parameters
could be more complicated than for a one compartment model. As shown in Figure 5, the
increase of the type I error of bioequivalence test based on EBE is linked to the shrinkage
which already appears with one compartment model. We think this relationship should be
similar for multi-compartmental models where more shrinkage is expected.
Conversely to the bias for estimates based on EBE, the bias for estimates based on NCA
depends on the number of samples per subject and is large for sparse design (N = 40, n = 3)
with high variability. Usually, NCA is used with rich designs where there are about ten to
twenty samples per subject. This method is not well suited for trials performed in patients
where the number of samples is often limited. In comparison to model-based approaches, the
estimation of parameters through NCA has several drawbacks. It is giving equal weight to
all concentrations without taking into account the measurement error. Furthermore, NCA is
sensitive to missing data, especially for the determination of Cmax and the computation of the
terminal slope. Even without missing data, the interpolation of the AUC between the last
sampling time and inﬁnity is very sensitive to the number of samples used to compute the
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terminal slope and could be problematic for atypical concentration proﬁles. This later issue
is perfectly illustrated by the simulation settings under Sh,h where 77% of the missing ÂUC i
are due to the two last concentrations increasing instead of decreasing. Contrary to NCA
estimates, there is no missing ÂUC i estimated by NLMEM due to this kind of PK proﬁles
because all subjects are analyzed together and information given by classical PK proﬁles oﬀ-
set information given by particular ones. NCA does not take into account all the knowledge
accumulated on the PK of the studied drug as each new analysis by NCA erases the past con-
trary to NLMEM. Finally, although we do not simulate such data, NCA applied to nonlinear
pharmacokinetics provides meaningless parameters and it cannot handle data below the limit
of quantiﬁcation. In this study, we choose to not introduce LOQ in the simulation because we
do not want to favour the SAEM algorithm which can ﬁt such data. We are aware that ﬁxing
some concentrations to 0.1 mg/L could introduce some bias. To avoid such arbitrary ﬁxing,
another common procedure is to resample until a valid value is obtained; however, resampling
can also introduce a bias. Anyhow, the proportion of ﬁxing value remains very low for Sl,l
and Sh,l. It is more important for Sh,h but it is responsible for only 12% of the missing ÂUC i
estimated by NCA.
When the number of samples per subject is large and the variability is not too high, tests
based on individual NCA estimates remain a good approach since they are simple and showed
satisfactory properties for both tested parameters. For Cmax and the sparse design, we ex-
pected an increase of the type I error because there is no sampling time corresponding to the
maximal concentration which is close to 2 h. But even with poor sample mean estimates, the
type I error is maintained at the nominal level of 5%. Though, for simulation with Sh,h, the
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type I error of AUC is very conservative (0.8%) which shows the limits of NCA for data with
high residual error.
Tests based on individual EBE have higher type I error than tests based on NCA estimates.
Our results on the type I error for Sl,l are consistent with the results obtained by Panhard and
Mentré with the same variability setting. For the sparse design, the type I error of tests based
on EBE is surprisingly high. In that case, EBE shrink towards their mean value and they are
more similar in both treatment groups. Therefore, the discrimination of the AUC or Cmax
between both treatment groups is more diﬃcult which leads to an increase of the type I error
(bioequivalence is obtained more easily). These results are consistent with the results of the
simulation study performed by Bertrand et al (37). In that work, they evaluate by simulation
the analysis of variance (ANOVA) performed on individual EBE to test the inﬂuence of a single
nucleotide polymorphism on a pharmacokinetic parameter of a drug. They show the impact
of the shrinkage on the power of ANOVA. The power is reduced when the shrinkage increases.
In other words, it is more diﬃcult to discriminate between the genotypes with high shrinkage
even when data are simulated with a diﬀerence.
As discussed by Schuirmann (26), the TOST procedure can be very conservative for highly
variable drugs. Consequently, several improvements of this procedure have been proposed as
in Berger et al (30), Brown et al (38) or Cao et al (39) to mention only a few. We are aware
that there is still a great arguing on which bioequivalence test should be performed. However,
we study only the classical TOST in this paper because our main objective is to compare the
same standard bioequivalence analysis recommended in the guidelines (1, 2) and performed on
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individual estimates obtained by two estimation methods (NCA and EBE). Nevertheless, in
this simulation study, the type I error of bioequivalence test performed on the true individual
simulated values is always at the nominal level of 5%, even for Sh,h where the variability is
particularly high. Therefore, we can conclude that, in this study, there is no issue about the
TOST procedure. Consequently, liberal or conservative type I errors of bioequivalence tests
performed on estimates cannot be imputed to the TOST but rather to the individual param-
eters estimation.
Tests based on individual estimates, NCA estimates or EBE, cannot be used for data with
high residual error or when the number of samples per subject is small. In those cases, the
type I error for tests based on NCA estimates is very poor or NCA estimates are biased and
the shrinkage of EBE induces an increase of the type I error. In these situations, other tests
based on a global analysis of all data should be considered. Panhard et al. already developed a
global bioequivalence Wald test based on NLMEM (14, 25). This test is directly performed on
the treatment eﬀect parameter after ﬁtting together the data of both treatment groups with
the estimation of within-subject variability. In this study, they also used the FOCE algorithm
implemented in nlme. Recently, Panhard and Samson developed an extension of the SAEM
algorithm for NLMEM including the estimation of the within-subject variability (40). How-
ever, the likelihood ratio test for bioequivalence has not been developed, due to the composite
null hypothesis. Additional methodological developments and simulations are needed to study
bioequivalence tests after global analysis of all PK data. This will be especially useful for drugs
with non linear pharmacokinetics and conditions where rich sampling is diﬃcult to achieve, i.e.
in pediatric studies or for drugs which cannot be administered in healthy subjects for safety
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reasons, such as oncology drugs.
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Appendix
Approximation of the variance of log(Cmax) by the delta method
For a one compartment model with ﬁrst order absorption and ﬁrst order elimination, Cmax is
deﬁned in Eq.(6) as a function of the three PK parameters, ka, CL/F and V/F . The variance
of log(Cmax), ω
2
Cmax , is approximated by the delta method (33) as:
ω2Cmax ≈
(
∂ log(Cmax)
∂ log(ka)
)2
log(µ)
ω2ka +
(
∂ log(Cmax)
∂ log(CL/F )
)2
log(µ)
ω2CL/F +
(
∂ log(Cmax)
∂ log(V/F )
)2
log(µ)
ω2V/F (13)
where log(µ) = (log(µka), log(µCL/F ), log(µV/F ))
′. After computing the derivatives, ω2Cmax can
be approximated by:
ω2Cmax ≈ ∆
2 (ω2ka + ω
2
CL/F ) + (∆− 1)
2 ω2V/F
with ∆ =
µCL/F (µCL/F − µka µV/F ) + µka µCL/F µV/F log
(
µka µV/F
µCL/F
)
(
µka µV/F − µCL/F
)2
(14)
In this simulation study, the general formula above is applied to approximate the variance of
log(Cmax) for both treatment groups (Ref and Test). Given the treatment eﬀect we simulate
for the treatment Test, both approximations, ω 2
C
(Ref)
max
and ω 2
C
(Test)
max
, are equal.
To approximate the variance of log(Cmax) by the delta method, we use the true simulated values
of µ (Ref) and Ω (Ref) described in section 2.2.3. To evaluate the delta method, we also estimate
the variance of log(Cmax), using the simulated parameter values of the rich design (N = 40,
n = 10) for the reference treatment, under Sl,l and Sh,l. For both variability settings, ω
2
C
(Ref)
max
is
estimated as the empirical variance of the 40000 true simulated values of log(Cmax
(Ref)
i ). For
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Sl,l, the standard deviation of log(Cmax) for the reference treatment expressed in percent is
10.5% both by simulation and the delta method. For Sh,l, it is 46.3% and 46.7% by simulation
and the delta method, respectively.
These results on the true simulated values validate the approximation of the variance of
log(Cmax) by the delta method. Consequently, we apply it to the data of each treatment group
for each simulated trial of the simulation study to approximate ω̂ 2
C
(Ref)
max
(ω̂ 2
C
(Test)
max
respectively)
using µ̂ (Ref) (µ̂ (Test) respectively) and Ω̂ (Ref) (Ω̂ (Test) respectively).
37
Table I: Summary of the three variability settings used in the simulation study. The between-
subject (BSV) and within-subject (WSV) variability are given as standard deviations of the
log-parameters multiply by 100 and expressed in percent.
Variability Sl,l Sh,l Sh,h
BSV
20% for ka and CL/F
50% 50%10% for V/F
WSV
10% for ka and CL/F
15% 15%5% for V/F
Residual error
a = 0.1 mg/L a = 0.1 mg/L a = 1 mg/L
b = 10% b = 10% b = 25%
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Table II: Type I error of the bioequivalence tests performed on the treatment eﬀect of log(AUC)
and log(Cmax) for each unilateral hypothesis, H0;80% and H0;125%. The type I error is estimated
from 1000 bioequivalence trials simulated under H0;80% or H0;125% for diﬀerent designs (N :
number of subjects, n: number of samples per subject), diﬀerent variability settings Sl,l, Sh,l
and Sh,h, for the true simulated values (SIM) and both types of estimates (NCA and EBE).
Due to the 1000 replicates, the 95% PI for a type I error of 5% is [3.7%; 6.4%].
N = 40, n = 10 N = 12, n = 10 N = 24, n = 5 N = 40, n = 3
SIM NCA EBE SIM NCA EBE SIM NCA EBE SIM NCA EBE
Sl,l AUC H0;80% 3.9 4.0 5.5 5.4 5.2 7.7 4.3 4.3 8.0 3.9 5.9 14.8
H0;125% 4.6 5.1 5.8 5.4 5.2 7.4 4.4 3.8 7.5 4.6 5.1 16.2
Cmax H0;80% 4.5 6.6 10.0 5.7 5.1 9.0 5.8 5.3 14.6 4.5 6.8 30.6
H0;125% 4.9 6.3 9.1 5.2 5.6 10.9 5.3 5.2 16.2 4.9 5.5 29.1
Sh,l AUC H0;80% 3.9 5.4 4.7 5.4 4.4 6.8 4.3 5.2 7.1 3.9 4.5 8.5
H0;125% 4.6 6.1 5.2 5.4 4.7 6.1 4.4 3.9 5.8 4.6 5.1 11.5
Cmax H0;80% 4.5 5.1 4.0 5.3 5.3 5.3 5.5 6.0 6.5 4.5 7.2 9.2
H0;125% 5.0 5.4 5.0 5.2 5.1 5.8 5.7 6.1 7.1 5.0 6.2 7.8
Sh,h AUC H0;80% 4.3 0.8 20.6
H0;125% 4.4 0.4 22.2
Cmax H0;80% 5.5 7.0 13.8
H0;125% 5.7 9.3 17.0
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Legend to figures
Figure 1. Concentrations (mg/L) simulated for the intermediate design (N = 24, n = 5) for
the reference treatment (left) and for the test treatment under H0;80% (middle) and H0;125%
(right) using the variability settings Sl,l (top), Sh,l (middle) and Sh,h (bottom).
Figure 2. Concentrations (mg/L) simulated for the original (N = 12, n = 10, left), interme-
diate (N = 24, n = 5, middle) and sparse (N = 40, n = 3, right) designs for the reference
treatment using the variability settings Sl,l (top) and Sh,l (bottom).
Figure 3. Bias (top) and root mean square error (RMSE, bottom) of estimates of the sample
mean for log(AUC) (left) and log(Cmax) (right) for the reference treatment from 1000 trials
for diﬀerent designs (N : number of subjects, n: number of samples per subject) and diﬀerent
variability settings Sl,l (◦), Sh,l () and Sh,h (△). The white symbols represent the individual
estimates obtained from NCA and the grey ones the individual estimates obtained from EBE.
Figure 4. Global type I error of the bioequivalence tests performed on the treatment eﬀect
of log(AUC) (top) and log(Cmax) (bottom). The global type I error is estimated from 1000
bioequivalence trials simulated under H0;80% and H0;125% for diﬀerent designs (N : number of
subjects, n: number of samples per subject) and diﬀerent variability settings Sl,l (◦), Sh,l ()
and Sh,h (△). The white symbols represent the individual estimates obtained from NCA and
the grey ones the individual estimates obtained from EBE. The dashed lines represent the
nominal level at 5% and its 95% prediction interval ([3.7%; 6.4%]).
Figure 5. Global Type I error of the bioequivalence tests performed on the treatment eﬀect
of log(AUC) (top) and log(Cmax) (bottom) versus the median shrinkage on the parameter of
interest for the reference treatment and diﬀerent simulation settings Sl,l (◦), Sh,l () and Sh,h
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(△). The rich design design (N = 40, n = 10) is represented by white symbols, the original
design (N = 12, n = 10) by light grey symbols, the intermediate design (N = 24, n = 5) by
dark grey symbols and the sparse design (N = 40, n = 3) by black symbols. The dashed lines
represent the nominal level at 5% and its 95% prediction interval ([3.7%; 6.4%]).
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